Innate Pharma (IPHA) Competitors

$1.83 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.90 +0.07 (+3.77%)

As of 05/22/2026 05:07 PM Eastern

IPHA vs. TBPH, ABUS, ORIC, XNCR, and KURA

Should you buy Innate Pharma stock or one of its competitors? MarketBeat compares Innate Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innate Pharma include Theravance Biopharma (TBPH), Arbutus Biopharma (ABUS), Oric Pharmaceuticals (ORIC), Xencor (XNCR), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry.

How does Innate Pharma compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Innate Pharma had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 1 mentions for Innate Pharma and 0 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score.

Company	Overall Sentiment
Theravance Biopharma	Neutral
Innate Pharma	Neutral

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Theravance Biopharma currently has a consensus target price of $21.83, suggesting a potential upside of 33.37%. Innate Pharma has a consensus target price of $5.00, suggesting a potential upside of 173.22%. Given Innate Pharma's higher possible upside, analysts plainly believe Innate Pharma is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Theravance Biopharma has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	7.85	$105.89M	$2.20	7.44
Innate Pharma	$10.19M	16.87	-$55.64M	N/A	N/A

Theravance Biopharma has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Innate Pharma's net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Innate Pharma	N/A	N/A	N/A

Summary

Theravance Biopharma beats Innate Pharma on 9 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Arbutus Biopharma?

Innate Pharma (NASDAQ:IPHA) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Innate Pharma presently has a consensus price target of $5.00, suggesting a potential upside of 173.22%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential upside of 14.94%. Given Innate Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Innate Pharma is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Innate Pharma had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 1 mentions for Innate Pharma and 0 mentions for Arbutus Biopharma. Innate Pharma's average media sentiment score of 0.00 equaled Arbutus Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Innate Pharma	Neutral
Arbutus Biopharma	Neutral

Innate Pharma has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Arbutus Biopharma has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.87	-$55.64M	N/A	N/A
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24

Arbutus Biopharma has a net margin of 83.95% compared to Innate Pharma's net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Arbutus Biopharma	83.95%	129.32%	112.24%

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Arbutus Biopharma beats Innate Pharma on 8 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Innate Pharma's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Innate Pharma	N/A	N/A	N/A

Oric Pharmaceuticals currently has a consensus price target of $19.36, suggesting a potential upside of 132.74%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 173.22%. Given Innate Pharma's higher possible upside, analysts plainly believe Innate Pharma is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Innate Pharma has higher revenue and earnings than Oric Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Innate Pharma	$10.19M	16.87	-$55.64M	N/A	N/A

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 1 mentions for Innate Pharma. Oric Pharmaceuticals' average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Innate Pharma beats Oric Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Xencor?

Innate Pharma (NASDAQ:IPHA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Innate Pharma currently has a consensus target price of $5.00, suggesting a potential upside of 173.22%. Xencor has a consensus target price of $24.50, suggesting a potential upside of 116.62%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Innate Pharma is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Innate Pharma has higher earnings, but lower revenue than Xencor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.87	-$55.64M	N/A	N/A
Xencor	$125.58M	6.68	-$91.92M	-$2.29	N/A

0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 4.8% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Innate Pharma has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Innate Pharma's return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Xencor	-177.10%	-28.77%	-20.52%

Innate Pharma has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Xencor has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

In the previous week, Xencor had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for Xencor and 1 mentions for Innate Pharma. Xencor's average media sentiment score of 0.56 beat Innate Pharma's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innate Pharma beats Xencor on 10 of the 15 factors compared between the two stocks.

How does Innate Pharma compare to Kura Oncology?

Innate Pharma (NASDAQ:IPHA) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Innate Pharma has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Innate Pharma's return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Kura Oncology	-411.19%	-141.95%	-43.28%

0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Innate Pharma has higher earnings, but lower revenue than Kura Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.87	-$55.64M	N/A	N/A
Kura Oncology	$67.48M	14.80	-$278.67M	-$3.35	N/A

In the previous week, Kura Oncology had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Innate Pharma. Kura Oncology's average media sentiment score of 0.30 beat Innate Pharma's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innate Pharma currently has a consensus target price of $5.00, suggesting a potential upside of 173.22%. Kura Oncology has a consensus target price of $26.38, suggesting a potential upside of 134.44%. Given Innate Pharma's higher possible upside, equities research analysts clearly believe Innate Pharma is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Innate Pharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Summary

Innate Pharma beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$171.88M	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.91	21.01	25.66
Price / Sales	16.87	329.35	615.84	111.99
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-7.04	7.09	10.37	7.14
Net Income	-$55.64M	$24.45M	$3.57B	$335.98M
7 Day Performance	-18.67%	5.45%	6.01%	3.56%
1 Month Performance	29.79%	2.43%	3.52%	2.54%
1 Year Performance	-15.08%	62.98%	34.13%	35.05%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	2.5885 of 5 stars	$1.83 flat	$5.00 +173.2%	-15.1%	$171.88M	$10.19M	N/A	220	Gap Up
TBPH Theravance Biopharma	3.3547 of 5 stars	$16.25 -0.1%	$21.83 +34.4%	+76.0%	$838.25M	$107.46M	7.39	110
ABUS Arbutus Biopharma	1.6572 of 5 stars	$4.20 +0.7%	$5.00 +19.0%	+35.1%	$823.73M	$14.08M	5.06	90	Gap Up
ORIC Oric Pharmaceuticals	1.7567 of 5 stars	$7.97 +0.5%	$19.36 +143.0%	+31.0%	$820.89M	N/A	N/A	80	Analyst Forecast
XNCR Xencor	2.0182 of 5 stars	$10.41 -5.9%	$24.50 +135.4%	+49.4%	$820.01M	$125.58M	N/A	280

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. TBPH, ABUS, ORIC, XNCR, and KURA

How does Innate Pharma compare to Theravance Biopharma?

Summary

How does Innate Pharma compare to Arbutus Biopharma?

Summary

How does Innate Pharma compare to Oric Pharmaceuticals?

Summary

How does Innate Pharma compare to Xencor?

Summary

How does Innate Pharma compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. TBPH, ABUS, ORIC, XNCR, and KURA

How does Innate Pharma compare to Theravance Biopharma?

Does the media refer more to TBPH or IPHA?

Do insiders & institutionals hold more shares of TBPH or IPHA?

Do analysts rate TBPH or IPHA?

Which has preferable earnings & valuation, TBPH or IPHA?

Which has more risk and volatility, TBPH or IPHA?

Is TBPH or IPHA more profitable?

Summary

How does Innate Pharma compare to Arbutus Biopharma?

Do analysts prefer IPHA or ABUS?

Does the media favor IPHA or ABUS?

Which has more risk and volatility, IPHA or ABUS?

Which has better earnings and valuation, IPHA or ABUS?

Is IPHA or ABUS more profitable?

Do institutionals & insiders have more ownership in IPHA or ABUS?

Summary

How does Innate Pharma compare to Oric Pharmaceuticals?

Is ORIC or IPHA more profitable?

Do analysts recommend ORIC or IPHA?

Do institutionals and insiders believe in ORIC or IPHA?

Which has more risk and volatility, ORIC or IPHA?

Which has preferable earnings and valuation, ORIC or IPHA?

Does the media refer more to ORIC or IPHA?

Summary

How does Innate Pharma compare to Xencor?

Do analysts recommend IPHA or XNCR?

Which has preferable valuation & earnings, IPHA or XNCR?

Do insiders and institutionals believe in IPHA or XNCR?

Is IPHA or XNCR more profitable?

Which has more risk & volatility, IPHA or XNCR?

Does the media prefer IPHA or XNCR?

Summary

How does Innate Pharma compare to Kura Oncology?

Is IPHA or KURA more profitable?

Do institutionals and insiders believe in IPHA or KURA?

Which has stronger valuation & earnings, IPHA or KURA?

Does the media prefer IPHA or KURA?

Do analysts rate IPHA or KURA?

Which has more risk & volatility, IPHA or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools